Flash Finance

Lincoln Pharmaceuticals LimitedLINCOLNCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹545.60
MCap ₹1,093 Cr · P/E 11.3
Lincoln Pharmaceuticals Limited — Stock analysis & AI research Lincoln Pharmaceuticals Limited — Seasonality — best & worst months Lincoln Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Lincoln Pharmaceuticals Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 Low P/E Stocks📋 Stocks Cheaper Than Their Industry📋 Stocks With Strong Quarterly Results📋 Low Debt Stocks 📈 Lowest Technical Score 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹177 Cr
Sales · Jun 2026
+15.1% YoY
₹27 Cr
Operating Profit · Jun 2026
+15.2% YoY
15.5%
OPM % · Jun 2026
+0.0% YoY
₹36 Cr
Net Profit · Jun 2026
+30.9% YoY
₹18.09
EPS · Jun 2026
+30.9% YoY

📝 Lincoln Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Lincoln Pharmaceuticals Limited reported revenue of ₹177 crore for the quarter ended June 2026 (Q1 FY27), up 15.1% from ₹154 crore in the same quarter last year, and down 5.2% sequentially over the March 2026 quarter.

Net profit rose 30.9% year-on-year to ₹36 crore, from ₹28 crore. Earnings per share (EPS) came in at ₹18.09.

Operating profit stood at ₹27 crore — an operating margin (OPM) of 15.5%, compared with 15.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Lincoln Pharmaceuticals Limited posted revenue of ₹671 crore, a growth of 7.6% over FY25, with a net profit of ₹88 crore (up 7.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹694 crore with a net profit of ₹97 crore.

Valuation snapshot

At the current price of ₹545.60, LINCOLN has a market capitalisation of ₹1,093 crore and a trailing P/E of about 11.3.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 11th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 49.78%, foreign institutional investors (FIIs) 5.20%, domestic institutional investors (DIIs) 1.08%, public shareholders 43.94% of Lincoln Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,093 Cr
Current Price ?
₹545.6
P/E ?
11.29below ind
Industry P/E ?
21.30
P/B ?
1.44
P/S ?
1.57
P/FCF ?
13.33
Enterprise Value ?
₹1,097 Cr
EV/EBITDA ?
10.81
PEG ?
1.61
Earnings Yield ?
7.9%
Dividend Yield ?
0.33%
Profitability & Returns
Sales (TTM) ?
₹694 Cr
OPM ?
14.6%
Profit after tax (TTM) ?
₹97 Cr
EPS (TTM) ?
₹48.34
ROCE ?
16.0%
ROE ?
12.8%
ROA ?
10.9%
Growth
Sales — latest qtr ?
₹177 Cr
PAT — latest qtr ?
₹36 Cr
YoY qtr sales growth ?
15.1%
YoY qtr profit growth ?
30.9%
Sales growth (3y) ?
10%
Sales growth (5y) ?
10%
Profit growth (3y) ?
7%
Profit growth (5y) ?
7%
Financial Health
Debt ?
₹4 Cr
Debt to Equity ?
0.01
Interest Coverage ?
112.4
Current Ratio ?
N/A
Ownership
Promoter holding ?
49.78%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-8.6%
Return 6 months ?
-7.1%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 134112136156146142147161147168154163166187177 +15.1% -5.2%
Operating Profit 271721313018232824272425242527 +15.2% +9.7%
Other Income 648911710109-715715-424 +58.9% +706.6%
Interest 010000001000000 +23.3% —
Depreciation 223333333334444 +11.7% -2.9%
Profit Before Tax 311725373822293529163529351748 +34.4% +179.7%
Net Profit 221319282819242621122820291236 +30.9% +202.0%
EPS 10.796.279.4913.8114.009.2811.8213.1510.375.7813.829.9814.285.8118.09 +30.9% +211.4%
OPM % 20.0% 14.8% 15.3% 20.0% 20.3% 12.9% 15.4% 17.6% 16.1% 15.9% 15.5% 15.6% 14.2% 13.4% 15.5% +0.0% +15.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹623 Cr ₹671 Cr ₹694 Cr +7.6%
Operating Profit ₹101 Cr ₹98 Cr ₹101 Cr -3.6%
OPM % 16.29% 14.58% 14.62% -10.5%
NPM % 13.21% 13.16% 13.95% -0.4%
Other Income ₹22 Cr ₹34 Cr ₹43 Cr +49.7%
Depreciation ₹13 Cr ₹15 Cr ₹15 Cr +14.9%
Interest ₹2 Cr ₹1 Cr ₹1 Cr -60.8%
EBIT ₹89 Cr ₹83 Cr ₹86 Cr -6.3%
PBT ₹109 Cr ₹116 Cr ₹128 Cr +6.2%
Tax ₹27 Cr ₹23 Cr ₹26 Cr -15.6%
Net Profit ₹82 Cr ₹88 Cr ₹97 Cr +7.2%
EPS ₹41.12 ₹43.89 ₹48.16 +6.7%
Material Cost ₹282 Cr ₹228 Cr ₹231 Cr -19.1%
Employee Cost ₹112 Cr ₹93 Cr ₹94 Cr -17.5%
Extraordinary Items ₹0 Cr ₹0 Cr ₹0 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 20202020 +0.0%
Reserves 482573652738 +13.2%
Borrowings 21-04 —
Other Liabilities 83106125128 +2.4%
Total Liabilities 587700797890 +11.7%
Fixed Assets 151179182191 +4.9%
CWIP 7345 +25.0%
Investments 91139174209 +20.1%
Other Assets 339379437486 +11.2%
Total Assets 587700797890 +11.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 396393106 +14.0%
Cash from Investing Activity -37-57-79-98 -24.1%
Cash from Financing Activity -4-5-60 +100.0%
Net Cash Flow -2188 +0.0%
Free Cash Flow 26247482 +10.8%
CFO/OP 77%89%117%135% +15.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 981029788 -9.3%
Inventory Days 1061019994 -5.1%
Days Payable 7795106100 -5.7%
Cash Conversion Cycle 1261089082 -8.9%
Working Capital Days 121121116239 +106.0%
ROCE % 22%22%17%16% -5.9%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 49.78%49.78%49.78%49.78% +0.0%
FIIs 5.13%4.73%4.70%5.20% +10.6%
DIIs 0.01%0.01%0.01%1.08% +10700.0%
Public 45.08%45.49%45.51%43.94% -3.4%
No. of Shareholders 31,78432,37031,02628,303 -8.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Lincoln Pharmaceuticals Limited's revenue in Q1 FY27?
Lincoln Pharmaceuticals Limited reported revenue of ₹177 crore for the quarter ended June 2026 (Q1 FY27), up 15.1% from ₹154 crore in the same quarter last year, and down 5.2% sequentially over the March 2026 quarter.
What was Lincoln Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 30.9% year-on-year to ₹36 crore, from ₹28 crore. Earnings per share (EPS) came in at ₹18.09.
What is LINCOLN's market capitalisation and P/E ratio?
At the current price of ₹545.60, LINCOLN has a market capitalisation of ₹1,093 crore and a trailing P/E of about 11.3.
Who owns Lincoln Pharmaceuticals Limited? (shareholding pattern)
As of Mar 2026, promoters held 49.78%, foreign institutional investors (FIIs) 5.20%, domestic institutional investors (DIIs) 1.08%, public shareholders 43.94% of Lincoln Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI